About Occlutech
Occlutech is a Healthcare company based in Schaffhausen (Switzerland) founded in 2003 by Tor Peters. It operates as a provider of minimally invasive cardiac devices for congenital heart defects, stroke prevention and heart failure. Occlutech has raised $70.81 million across 2 funding rounds from investors including Carnegie, Fjarde AP-fonden and interlinksinvestments.co.uk. Occlutech has completed 1 acquisition, including NonWoTecc Medical. Its chief executive is Tor Peters. Occlutech offers products and services including Occluders, ATRIAL FLOW REGULATOR, and Accessories. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Medical Devices and Therapeutic Devices. Its legal entity is Occlutech Holding AG. Its competitors include Xeltis, PECA Labs, Endonovo Therapeutics, Coherex and CoAptus Medical and 3 more; 5 of its 8 listed competitors have raised funding.
Company details
Occlutech was founded in 2003 in Schaffhausen, Switzerland, within the cardiovascular medical devices sector. Devices for minimally invasive treatments of congenital heart defects, stroke prevention, and heart failure are developed and supplied. These include ASD occluders, cardiac implants, and accessories targeted at conditions such as Atrial Septal Defect, Patent Foramen Ovale, Left Atrial Appendage closure, Patent Ductus Arteriosus, and paravalvular leaks. Operations focus on structural heart interventions across global markets.
- Headquarters Schaffhausen, Switzerland
- Founders Tor Peters
- SectorsHealthcare
- Email••••••••
- Website occlutech.com
- Social LinkedIn YouTube
- Legal Name Occlutech Holding Ag
- Total Equity Funding$70.81M (USD)
in 2 rounds
- Latest Funding Round$49.19M (USD), Series C
Dec 2021
- InvestorsCarnegie
& 2 more
- Investments & Acquisitions
Products & Services of Occlutech
Occlutech offers a comprehensive portfolio of products and services, including Occluders, ATRIAL FLOW REGULATOR, and Accessories.
Devices for closing heart defects in congenital diseases
Regulator to manage atrial flow and improve heart function
Support tools for cardiac implant procedures and placements
Apps and channels of Occlutech
its YouTube channel Occlutech has 760 subscribers and 30 videos.
Videos from Occlutech
The most watched videos on Occlutech's YouTube channel, Occlutech (760 subscribers). Click a video to play it here.
More on Occlutech.
Funding Insights of Occlutech
Occlutech has successfully raised a total of $70.81M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $49.19 million completed in December 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $70.81M
- Total Rounds 2
- Last Round Series C — $49.19M
- First Round $21.62M
(Aug 2011)
- Investors Count 3
All 2 funding rounds of Occlutech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2021 | $49.19M | Series C | – | Carnegie, Fjarde AP-fonden | – |
| Aug 2011 | $21.62M | Series B | – | interlinksinvestments.co.uk | – |
3 investors in total: 3 institutional.
Investors in Occlutech
Occlutech has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Carnegie, Fjarde AP-fonden and interlinksinvestments.co.uk.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Financial services are provided by Carnegie in investment and private banking. | 1803 | carnegie.se | Stockholm, Sweden | |
Manages Swedish national pension assets with sustainable investment strategies. | 2001 | ap4.se | Stockholm, Sweden | |
- | – | interlinksinvestments.co.uk | - |
Investor details for Occlutech
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Occlutech
2 people are tracked at Occlutech (2 in leadership).
| Name | Role | Group |
|---|---|---|
Tor Peters | Founder & CEO | Leadership |
Yilmaz Karakis | Managing Director | Leadership |
Complete people profiles for Occlutech
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Occlutech
Occlutech has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include NonWoTecc Medical.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Vascular prostheses are developed for peripheral and coronary applications. | nonwotecc.de | Cologne, Germany | 2007 | Jan 2013 | •••• |
Complete acquisition details for Occlutech
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Occlutech
4 dated milestones of Occlutech across 18 years, from founding to its latest funding, stage changes and deals.
- Founded Occlutech is founded.
- Funding First funding round of $21.6M.
- Acquisition Acquires NonWoTecc Medical.
- Funding Latest funding round, Series C, of $49.2M.
Competitors of Occlutech
Occlutech has 8 listed competitors in our database, 5 of them funded. They include Xeltis, PECA Labs, Endonovo Therapeutics, Coherex and CoAptus Medical, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| xeltis.com | 2006 | Zurich, Switzerland | $164.42M | – | Developer of bioabsorbable synthetic heart valves and vascular grafts | |
| pecalabs.com | 2011 | Pittsburgh, United States | $19.91M | – | Pediatric cardiac surgical devices are developed for congenital heart defects. | |
| endonovo.com | 2011 | Los Angeles, United States | – | – | Bioelectronic devices are developed for regenerative medicine therapies. | |
| coherex.com | 2003 | Salt Lake, United States | $25.03M | 19 | Structural heart disease conditions are addressed with implant devices. | |
| coaptus.com | 2003 | Redmond, United States | $3M | 40 | Develops non-implant therapeutics for treating patent foramen ovale, a structural heart defect. | |
| cardia.com | 1998 | Eagan, United States | – | – | Products for transvenous closures of certain types of congenital heart defects. | |
| amplatzer.com | 1995 | Plymouth, United States | – | – | Devices to treat congenital heart diseases and peripheral vascular diseases | |
| elevatedcpr.com | 2015 | Edina, United States | $9.51M | – | CPR products for sudden cardiac arrest treatment are developed. |
Detailed competitors of Occlutech
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Occlutech
The website of Occlutech (occlutech.com) receives about 5.4K visits a month.
- Monthly visits5.4K
▲ 23% vs previous month
Websites whose visitors overlap most with Occlutech. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
medicinalive.com | medicinalive.com | 100% | – | #11,060,960 | – |
gehealthcare.de | gehealthcare.de | 95% | – | #1,487,641 | – |
medicina360.com | medicina360.com | 88% | – | #1,453,921 | – |
gesundheitsindustrie-bw.de | gesundheitsindustrie-bw.de | 63% | – | #1,750,575 | – |
Top companies in Cardiac and Vascular Disorders
10 companies that operate in the same segment as Occlutech (Cardiac and Vascular Disorders), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Connected devices for health, sleep, and activity monitoring are developed. | 2008 | Moulineaux, Seine-maritime, France | USD 93.83 M | – | – | |
SMT is recognized as a developer of cardiovascular medical devices. | 1998 | Surat, Gujarat, India | – | USD 106.25 M | 1,090 | |
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | – | 255 | |
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 | |
Cloud-based ambulatory ECG monitors for cardiac arrhythmia diagnosis are provided. | 2006 | San Francisco, California, United States | USD 109.23 M | USD 747.14 M | 2,000 | |
Provider of neuroprotection devices for carotid artery disease | 2007 | Sunnyvale, California, United States | USD 241.8 M | – | – | |
Miniaturized wireless implantable sensors are developed for hemodynamic monitoring. | 2007 | East Peoria, Illinois, United States | USD 154.77 M | – | 104 | |
Access catheters for neurovascular stroke treatment are provided. | 2015 | Campbell, California, United States | USD 596 M | – | – | |
Biosensor patches are developed for monitoring multiple body vitals. | 2011 | Campbell, California, United States | USD 239.95 M | – | 184 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Occlutech
Complete news archive for Occlutech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Occlutech
Occlutech was founded in 2003 and raised its 1st funding round 8 years after it was founded.
Occlutech is headquartered in Schaffhausen, Switzerland. It is registered at Schaffhausen, Schaffhausen, Switzerland.
Tor Peters is the current CEO of Occlutech. They have also founded this company.
Occlutech is a funded company, having raised a total of $70.81M across 2 funding rounds to date. The company's 1st funding round was a Series B of $21.62M, raised on Aug 2011.
Occlutech was founded in 2003 in Schaffhausen, Switzerland, within the cardiovascular medical devices sector. Devices for minimally invasive treatments of congenital heart defects, stroke prevention, and heart failure are developed and supplied. These include ASD occluders, cardiac implants, and accessories targeted at conditions such as Atrial Septal Defect, Patent Foramen Ovale, Left Atrial Appendage closure, Patent Ductus Arteriosus, and paravalvular leaks. Operations focus on structural heart interventions across global markets.
Occlutech's top competitors include Xeltis, PECA Labs and Endonovo Therapeutics.
Occlutech offers Occluders, ATRIAL FLOW REGULATOR, and Accessories.
Occlutech has made 1 acquisition, including NonWoTecc Medical.
Occlutech has 3 investors. Key investors include Carnegie, Fjarde AP-fonden, and interlinksinvestments.co.uk.
Occlutech operates through Occlutech Holding Ag.